Sort   by:  
 Page size 
UnknownImpact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Not available
S-EPMC9361393 | biostudies-literature
UnknownLow toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.
Not available
S-EPMC7606268 | biostudies-literature
UnknownMicrobiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation.
Not available
S-EPMC9057614 | biostudies-literature
UnknownOptimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Not available
S-EPMC9006295 | biostudies-literature
UnknownHigher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Not available
S-EPMC9979765 | biostudies-literature
UnknownDisease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Not available
S-EPMC9384925 | biostudies-literature
UnknownToxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Not available
S-EPMC6933289 | biostudies-literature
Sort   by:  
 Page size